Inhibrx is a privately held, science-first, self-sustainable biotherapeutic company. Inhibrx developed an efficient and productive scientific and business approach to align the incentives of our scientific team, collaborators, biotech and pharmaceutical partners and investors to rapidly develop transformative therapeutics for patients in need.
Founder, Chief Executive Officer
Mark founded Inhibrx with Brendan Eckelman and Quinn Deveraux in 2010 and served as the Chief Executive Officer since the companyâ€™s inception. »
Brendan Eckelman, Ph.D.
Founder, Chief Operating Officer
Brendan is a co-founder of Inhibrx and serves as its Chief Operating Officer and VP of Biotherapeutics. »
Quinn Deveraux, Ph.D., Founder
Chief Scientific Officer
Quinn leads the target identification, validation and therapeutic lead selection and oversees the development strategy for Inhibrxâ€™s biotherapeutic pipeline. »
Klaus W. Wagner, M.D., Ph.D.
Chief Medical Officer
Klaus leads the clinical translation of Inhibrxâ€™s biotherapeutic pipeline. »
Matthew Cohen, J.D.
Matt leads legal affairs at Inhibrx. Prior to joining Inhibrx, Matt served as Senior Vice President, General Counsel and Corporate Secretary of GenMark Diagnostics. »
John Timmer, Ph.D.
VP of Research
John leads single domain antibody discovery projects and biotherapeutic development at Inhibrx. He has been instrumental in developing Inhibrx's multispecific antibody formats for conditional immune activation. »
Stuart Bussell, Ph.D.
VP of Development
Stuart leads process development and product manufacturing activities at Inhibrx, including sub-teams for upstream and downstream process development and analytical and formulation development. »